Background: Treatment of pandrug-resistant isolates often necessitates combination therapy. Checkerboard synergy and time-killing assay tests were performed to evaluate the benefits of a triple combination with meropenem, ertapenem, and colistin against 10 colistin-resistant K. pneumoniae clinical isolates harboring different β-lactamases. (bla, bla).
Materials And Methods: In this study, ertapenem and meropenem (ERT/MEM), meropenem and colistin (MEM/COL), ertapenem, meropenem and colistin (ERT/MEM/COL) combinations were tested using checkerboard techniques and time-kill assays of each antibiotic alone and in combination against 10 colistin-resistant clinical K. pneumoniae isolates. An analysis of K. pneumoniae isolate B6 using a scanning electron microscope revealed morphologic changes in the cell surface after treatment with each antibiotic both alone and in combination. The whole genome of K. pneumoniae KPNB1 was sequenced using an Ion Torrent PGM sequencer.
Results: According to the checkboard results, synergistic combinations were observed with ertapenem/meropenem (5/10 isolates), meropenem/colistin (7/10) and ertapenem/meropenem/colistin (9/10); no antagonism was observed for all combinations. For the time-kill assay results; synergism and bactericidal effects were observed with meropenem/colistin (10/10) and with ertapenem/meropenem/colistin (10/10) combinations, and an indifference effect was observed with the ertapenem and meropenem (10/10) combination. Strain number 1 was found 100% identical to Klebsiella pneumoniae subsp. pneumoniae HS11286 according to the outcomes of complete genome sequence analysis, and the strain carried the genes bla, bla, blaNDM, arr-3, aac (6')-Ib-cr, rmtF, and catB1.
Conclusion: Using double carbapenem antibiotics with colistin could be a potential alternative to treat colistin and carbapenem-resistant K. pneumoniae. The present study is the first Turkish report of OXA-181-type carbapenemase causing colistin resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238654 | PMC |
| http://dx.doi.org/10.1186/s13756-020-00727-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Instant messaging for outpatient intramuscular antibiotic therapy adherence: proof of concept.
J Infect Dev Ctries
November 2024
Department of Infectious Diseases, School of Medicine, University Hospital Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Objective: Outpatient antimicrobial therapy works but often requires in-person oversight. Advancements enable seamless communication. We used instant messaging to track adherence, cost, efficacy, and adverse events for outpatient intramuscular antibiotic therapy.
View Article and Find Full Text PDFGeographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
PLoS One
December 2024
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations.
Methods: We systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE.
Antibacterial and antifungal drug concentrations in intra-abdominal abscesses: a prospective clinical study.
Antimicrob Agents Chemother
December 2024
Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Secondary peritonitis with intra-abdominal abscesses (IAA) is difficult to treat because of the supposed low rate of penetration of antimicrobial drugs at the site of infection. However, clinical data about the actual bioavailability of antimicrobial drugs in IAA are scarce. This prospective observational study aimed at assessing the drug penetration in IAA of the antibiotics (piperacillin-tazobactam, carbapenems) and antifungals (fluconazole, echinocandins) that are usually recommended for the treatment of intra-abdominal infections.
View Article and Find Full Text PDFDoripenem, Ertapenem, and Meropenem Sensitivity in Salmonella Typhi: A Cross-Sectional Study From Pakistan.
Cureus
November 2024
Department of Pharmacy, Hayatabad Medical Complex, Peshawar, PAK.
Background Typhi ( Typhi) is increasingly resistant to multiple antibiotics, posing a challenge in treatment, particularly in multidrug-resistant (MDR) cases. Carbapenems, including doripenem, ertapenem, and meropenem, have been considered last-resort options. This study evaluates the effectiveness of these carbapenems against Typhi isolates in a clinical setting in Peshawar, Pakistan.
View Article and Find Full Text PDFProfile of bacterial resistance in emergency wards, non-intensive care unit areas, and intensive care units in Mexican hospitals with the antimicrobial stewardship program.
IJID Reg
December 2024
MSD, Mexico City, México.
Objectives: Bacterial infections are important causes of death. Some reports have shown that the COVID-19 pandemic may have had an impact on drug resistance. The objective of this work was to compare the resistance profiles between 2019 and 2020 in the emergency department, non-intensive care units (ICU), and ICU areas in Mexican hospitals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!